Zambia AIDS Malignancies Diagnosis and Pathogenesis Program Supplement

摘要 赞比亚艾滋病恶性诊断和发病计划(ZAMDAPP)的建立将 支持美国和赞比亚的合作，以发展强大的癌症研究基础设施 赞比亚癌症医院(CDH)和大学教学医院(UTH)，初期重点是 卡波西肉瘤(KS)和眼表鳞状瘤病(OSSN)--最常见的两种 该国与艾滋病毒/艾滋病相关的恶性肿瘤。ZAMDAPP将首次通过以下方式提供一种机制 由赞比亚科学家领导的R01式研究项目通过Fogarty国际艾滋病培训中心 国际研究和培训计划(AITRP，D43TW001429)和艾滋病恶性疾病培训和 研究计划(AMTRP，D43TW010354)可能在三个对癌症研究至关重要的领域进行- 病毒学、生物统计学和流行病学以及癌症诊断学。领导这项研究的赞比亚人员 项目将受益于美国合作伙伴的指导和一些核心研究机构的支持。 ZAMDAPP将利用CDH和UTH在临床护理和治疗方面的优势；在分子病毒方面的优势 内布拉斯加州大学林肯分校的肿瘤学研究和癌症基因组学；以及病理学方面的优势， 流行病学和内布拉斯加州大学医学中心的生物统计学，同时扩展了 通过AITRP和AMTRP完成，这两个项目为学员继续深造提供支持 学位。除了提供研究经费外，ZAMDAPP还将在 美国和赞比亚将聘请下一代赞比亚癌症研究人员，增加当地 专业知识，并加强技术转让。这一伙伴关系将导致建立 进行高质量和可持续的癌症研究所需的技术和人员基础设施 赞比亚迫切需要。将实现三个具体目标：1)开展癌症研究 通过建立和加强两个研究核心设施，在UTH和CDH建设基础设施；2) 为前Fogarty培训的研究员提供机会，在这两个项目中领导假设驱动的研究项目 更普遍的艾滋病相关恶性肿瘤KS和OSSN，在美国合作伙伴和 核心设施；以及3)通过国内开发新一代赞比亚癌症研究人员的管道 讲习班，b)试点项目资金，c)美国短期技术培训。ZAMDAPP将在 由PI和领导层领导的成功的Fogarty和国家癌症研究所培训计划 撒哈拉以南非洲团队；实施跨学科研究和培训计划 培训轨道和国内研究项目，将赞比亚和美国的研究人员以及 有机会进行假设驱动的研究项目；成为赞比亚人的驱动者并受益于广泛的 当地的支持。因此，ZAMDAPP有很大潜力成功实现其目标。

ABSTRACT The establishment of the Zambia AIDS Malignancies Diagnosis and Pathogenesis Program (ZAMDAPP) will support the U.S.-Zambia collaborations necessary to develop a robust cancer research infrastructure at Zambia’s Cancer Diseases Hospital (CDH) and University Teaching Hospital (UTH), with an initial focus on Kaposi’s sarcoma (KS) and ocular surface squamous neoplasia (OSSN) – two of the most common occurring HIV/AIDS-associated malignancies in the country. ZAMDAPP will, for the first time, provide a mechanism by which R01-style research projects led by Zambian scientists trained through the Fogarty International AIDS International Research and Training Program (AITRP, D43TW001429) and AIDS Malignancies Training and Research Program (AMTRP, D43TW010354) may be conducted in three areas critical to cancer research – virology, biostatistics and epidemiology, and cancer diagnostics. The Zambian personnel leading the research projects will benefit from mentoring by U.S. partners and support by a number of research core facilities. ZAMDAPP will leverage strengths in clinical care and treatment at CDH and UTH; strengths in molecular viral oncology research and cancer genomics at the University of Nebraska-Lincoln; and strengths in pathology, epidemiology, and biostatistics at the University of Nebraska Medical Center, while extending the work that has been accomplished through AITRP and AMTRP, which provide support for trainees to pursue advanced degrees. In addition to providing research funding, ZAMDAPP will provide diverse training activities in the United States and Zambia to engage the next generation of Zambian cancer researchers, increase local expertise, and enhance the transfer of technology. The partnership will lead to exchanges that build the technical and personnel infrastructure necessary to perform the high-quality and sustainable cancer research desperately needed in Zambia. Three specific aims will be accomplished: 1) develop the cancer research infrastructure at UTH and CDH through the establishment and enhancement two research core facilities; 2) provide an opportunity for former Fogarty trained fellows to lead hypothesis-driven research projects in the two more prevalent AIDS-associated malignancies, KS and OSSN, with the support of the U.S. partners and the core facilities; and 3) develop a pipeline of next generation Zambian cancer researchers through a) in-country workshops, b) pilot project funding, and c) short-term U.S. technical training. ZAMDAPP will build on successful ongoing Fogarty and National Cancer Institute training programs led by the PI and the leadership team in sub-Saharan Africa; implement a cross-disciplinary research and training program with different training tracks and in-country research projects that pair Zambian and U.S. researchers along with opportunities to conduct hypothesis-driven research projects; and be Zambian driven and benefit from broad local support. Thus, there is strong potential for ZAMDAPP to success in reaching its goal.